Today's Top 5
5. Reimagining Oncology Clinical Trials
In our paper "Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms", we advocate for:
— Kamal S Saini, MD (@KSainiMD) November 22, 2021
- Optimal use of technology
- Reduced bureaucracy
- Greater patient centricityhttps://t.co/xufPwMkNA9@curijoey @aftimosp @kevinpunie @JavierCortesMD @OncoAlert
4. Lung Cancer Proteome Subtypes
🆕@NatureCancer🔥
— Antonio Passaro, MD PhD (@APassaroMD) November 23, 2021
Identified 6 distinct #lungcancer proteome subtypes w/ striking differences in immune cell composition & subtype-spec expression of immune checkpoints suggesting potential clinical value for tailored treatm stratification#LCSM 👏Amazinghttps://t.co/gmvdfb5ttm pic.twitter.com/xoFwXGdtIs
3. Targets for Cancer Vaccines
A nice highlight of our recent work in @LabJacks @kochinstitute in the @OncologyTimes. I enjoyed answering their questions! https://t.co/ayYpD29YDB
— Megan Burger (@MeganBurgerPhD) November 19, 2021
2. Drug Development in Sarcoma
FDA approved nab-sirolimus for patients with PEComa. Yet another ultra-rare sarcoma where our understanding of driver alterations led to rational drug testing and regulatory approval. Sarcoma: an ideal field for drug development, given the genetic diversity and unmet medical need
— Patrick Schöffski (@schoffski) November 23, 2021
1. Diversity Events at ASH 2021
Amazing line-up of Diversity, Equity, and Inclusion events at #ASH21
— Pat McGann, M.D. (@PTMcGann) November 24, 2021
Heath Equity Rounds
Anti-Racism Studio
Plenty of abstracts/educational sessions focusing on equity/ disparities
Great to see these topics prioritized at a heavily scientific meeting https://t.co/VkHIupnS2e